Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,424
archived clinical trials in
Cognitive Studies

Mild Cognitive Impairment and Obstructive Sleep Apnea
Mild Cognitive Impairment and Obstructive Sleep Apnea
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Mild Cognitive Impairment and Obstructive Sleep Apnea
Mild Cognitive Impairment and Obstructive Sleep Apnea
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Mild Cognitive Impairment and Obstructive Sleep Apnea
Mild Cognitive Impairment and Obstructive Sleep Apnea
Status: Enrolling
Updated:  12/31/1969
George Mason University
mi
from
Fairfax, VA
Mild Cognitive Impairment and Obstructive Sleep Apnea
Mild Cognitive Impairment and Obstructive Sleep Apnea
Status: Enrolling
Updated: 12/31/1969
George Mason University
mi
from
Fairfax, VA
Click here to add this to my saved trials
Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery
Feasibility Study of Vascular and Cognitive Assessments During Adjuvant Chemotherapy for Breast Cancer (VASCOG)
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery
Feasibility Study of Vascular and Cognitive Assessments During Adjuvant Chemotherapy for Breast Cancer (VASCOG)
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status: Enrolling
Updated:  12/31/1969
Legacy Emanuel Hospital
mi
from
Portland, OR
Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status: Enrolling
Updated: 12/31/1969
Legacy Emanuel Hospital
mi
from
Portland, OR
Click here to add this to my saved trials
Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status: Enrolling
Updated:  12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status: Enrolling
Updated: 12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status: Enrolling
Updated:  12/31/1969
Vanderbilt Children's Hospital
mi
from
Nashville, TN
Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status: Enrolling
Updated: 12/31/1969
Vanderbilt Children's Hospital
mi
from
Nashville, TN
Click here to add this to my saved trials
Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status: Enrolling
Updated:  12/31/1969
University Of Utah Hospital
mi
from
Salt Lake City, UT
Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status: Enrolling
Updated: 12/31/1969
University Of Utah Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status: Enrolling
Updated:  12/31/1969
British Columbia Children's Hospital
mi
from
Vancouver,
Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment
Status: Enrolling
Updated: 12/31/1969
British Columbia Children's Hospital
mi
from
Vancouver,
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Banner Health
mi
from
Phoenix, AZ
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Banner Health
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Banner Health
mi
from
Phoenix, AZ
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Banner Health
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC Davis
mi
from
Davis, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC Davis
mi
from
Davis, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC, Irvine
mi
from
Irvine, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC Irvine
mi
from
Orange, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC Irvine
mi
from
Orange, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC San Francisco
mi
from
San Francisco, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC San Francisco
mi
from
San Francisco, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC San Francisco
mi
from
San Francisco, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC San Francisco Memory Center
mi
from
San Francisco, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC San Francisco Memory Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Mt Sinai Medical Center
mi
from
Miami Beach, FL
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Mt Sinai Medical Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
University of Kansas
mi
from
Kansas City, KA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
University of Kansas
mi
from
Kansas City, KA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Duke University
mi
from
Durham, NC
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Wake Forest University
mi
from
Winston-Salem, NC
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Jefferson
mi
from
Philadelphia, PA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Jefferson
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Butler Hospital
mi
from
Providence, RI
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Butler Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
The University of Tennessee
mi
from
Knoxville, TN
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
The University of Tennessee
mi
from
Knoxville, TN
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Vanderbilt
mi
from
Nashville, TN
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Vanderbilt
mi
from
Nashville, TN
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UTSW
mi
from
Dallas, TX
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UTSW
mi
from
Dallas, TX
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UTSW
mi
from
Dallas, TX
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UTSW
mi
from
Dallas, TX
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UTSW
mi
from
Dallas, TX
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UTSW
mi
from
Dallas, TX
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Effects of Atomoxetine in Mild Cognitive Impairment
A 6 Month, Phase II Randomized, Double-Blind, Placebo Controlled, Flexible Dosing, Crossover Trial of Atomoxetine in Subjects With Mild Cognitive Impairment.
Status: Enrolling
Updated:  12/31/1969
Emory University School of Medicine
mi
from
Atlanta, GA
Effects of Atomoxetine in Mild Cognitive Impairment
A 6 Month, Phase II Randomized, Double-Blind, Placebo Controlled, Flexible Dosing, Crossover Trial of Atomoxetine in Subjects With Mild Cognitive Impairment.
Status: Enrolling
Updated: 12/31/1969
Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
Mild Neurocognitive Disorder in HIV Infection of the Brain
Inflammation and Function of P-gp in HIV Infection of Brain
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Mild Neurocognitive Disorder in HIV Infection of the Brain
Inflammation and Function of P-gp in HIV Infection of Brain
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sun City, AZ
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sun City, AZ
Click here to add this to my saved trials
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Long Beach, CA
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Francisco, CA
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials